{'fraction_non_alphanumeric': 0.021040974529346623, 'fraction_numerical': 0.007751937984496124, 'mean_word_length': 5.550724637681159, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Octreotide LAR® treatment throughout pregnancy in an acromegalic woman

We report a 24‐year‐old woman with active acromegaly despite pituitary surgery and irradiation who received continuous octreotide LAR® treatment for the control of GH excess throughout her pregnancy. The patient delivered a healthy girl following an uneventful pregnancy. Despite a substantial materno–fetal transfer of octreotide, postnatal development was normal with length parameters around the 50th percentile at 3 months of age. In almost all previously described cases (n = 13) octreotide was stopped after the diagnosis of pregnancy was established. No side‐effects of mother or fetus have been reported. Octreotide treatment in pregnancy seems to be feasible and safe. Due to the still‐limited number of reported cases, the potential benefits of octreotide treatment should be weighed carefully against its possible risks.